Probability of long-term glioblastoma survival assessed

Probability of long-Term  glioblastoma survival assessed

(HealthDay) -- Although the overall mortality rate of glioblastoma is high, compared with patients newly diagnosed with glioblastoma, those who survive two years or more after diagnosis have a favorable conditional probability of future survival, according to a study published online May 8 in Cancer.

To investigate the conditional probability of survival, Derek R. Johnson, M.D., of the Mayo Clinic in Rochester, Minn., and colleagues conducted a population-based analysis using , , and End Results data from 10,022 patients diagnosed with glioblastoma between 1998 and 2008 who had been treated with radiation-containing regimens.

The researchers found that median survival for the cohort was 12.61 months. At diagnosis, the conditional probability of surviving an additional two years was 19.8 percent and this increased to 65.9 percent at five years after diagnosis. Compared with patients diagnosed in 1998 to 2004, an increased proportion of patients diagnosed in 2005 to 2008 survived 12 months from diagnosis and from six, 12, and 18 months after diagnosis. Age was the only factor associated with a higher risk of death at diagnosis and at one and three years following diagnosis.

"Patients surviving past two years from diagnosis have a relatively favorable conditional probability of survival into the future compared to newly diagnosed patients," the authors write. "This effect becomes more pronounced with increasing time since . These data will assist in the counseling of glioblastoma survivors."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

10 hours ago

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, ...

Cancer exosome 'micro factories' aid in cancer progression

14 hours ago

Exosomes, tiny, virus-sized particles released by cancer cells, can bioengineer micro-RNA (miRNA) molecules resulting in tumor growth. They do so with the help of proteins, such as one named Dicer. New research from The University ...

User comments